PTK2 and cancer: A possible explanation may be that PRL can also signal through other effectors, including Focal Adhesion Kinase (FAK), Src-Family Kinases (SFKs), and ERK1/2 [15–17], which may enable aggressive luminal cancers to co-opt PRL signals for pro-tumorigenic purposes.